Perrigo (PRGO) Operating Income (2012 - 2026)
Perrigo's (PRGO) quarterly Operating Income came in at -$372.3 million in Q1 2026, down 893.82% year-on-year from $46.9 million in Q1 2025, and up 71.07% on a QoQ basis from -$1.3 billion in Q4 2025.
Perrigo (PRGO) Operating Income (2012 - 2026) Analysis & Trends
Perrigo (PRGO) has 15 years of Operating Income data on file, last reported at -$372.3 million in Q1 2026.
- On a quarterly basis, Operating Income fell 893.82% year-over-year to -$372.3 million in Q1 2026; TTM through Mar 2026 was -$1.5 billion, a 816.93% decrease from a year earlier, with the FY2025 full-year figure at -$1.1 billion, down 1093.98% from the prior year.
- Operating Income for Q1 2026 stood at -$372.3 million, up from -$1.3 billion in the prior quarter.
- Over the last five years, Operating Income for PRGO reached as high as $114.2 million in Q4 2024 and fell as low as -$1.3 billion in Q4 2025.
- Historically, Operating Income has averaged -$67.7 million across 5 years, with a median of $33.1 million in 2022.
- Across the five-year window, Operating Income surged 923.19% in 2023 and sank 1227.06% in 2025, its largest moves.
- Year by year, Operating Income stood at $31.0 million in 2022, then slumped by 150.32% to -$15.6 million in 2023, then soared by 832.05% to $114.2 million in 2024, then sank by 1227.06% to -$1.3 billion in 2025, then surged by 71.07% to -$372.3 million in 2026.
- Per Business Quant data, the three most recent Operating Income figures were -$372.3 million in Q1 2026, -$1.3 billion in Q4 2025, and $72.6 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | 652.00 Mn |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | 833.00 Mn |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | -2.65 Bn |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | 325.80 Mn |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | -79.70 Mn |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | 193.40 Mn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | 291.00 Mn |
| 10 | Perrigo | 1.40 Bn | 1.04 Bn | 325.50 Mn | -372.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 28, 2026 | -372.30 Mn |
| Dec 31, 2025 | -1.29 Bn |
| Sep 27, 2025 | 72.60 Mn |
| Jun 28, 2025 | 45.40 Mn |
| Mar 29, 2025 | 46.90 Mn |
| Dec 31, 2024 | 114.20 Mn |
| Sep 28, 2024 | 80.40 Mn |
| Jun 29, 2024 | -26.50 Mn |
| Mar 30, 2024 | -55.20 Mn |
| Dec 31, 2023 | -15.60 Mn |
| Sep 30, 2023 | 62.10 Mn |
| Jul 1, 2023 | 56.80 Mn |
| Apr 1, 2023 | 48.50 Mn |
| Dec 31, 2022 | 31.00 Mn |
| Oct 1, 2022 | 33.10 Mn |
| Jul 2, 2022 | -6.90 Mn |
| Apr 2, 2022 | 21.70 Mn |
| Dec 31, 2021 | 46.70 Mn |
| Oct 2, 2021 | 438.30 Mn |
| Jul 3, 2021 | -125.90 Mn |